Difficult to Treat Proteeae strains in high risk Romanian hospital departments
By:
References
- 1. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012 Mar;18(3):268–81. DOI: 10.1111/j.1469-0691.2011.03570.x10.1111/j.1469-0691.2011.03570.x21793988
- 2. Kadri S, Adjemian J, Lai Y, Spaulding A, Ricotta E, Prevots D, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Jul 23;67. DOI: 10.1093/cid/ciy37810.1093/cid/ciy378626017130052813
- 3. Gajdács M, Bátori Z, Ábrók M, Lázár A, Burián K. Characterization of Resistance in Gram-Negative Uri-nary Isolates Using Existing and Novel Indicators of Clinical Relevance: A 10-Year Data Analysis. Life (Basel, Switzerland). 2020 Feb;10(2). DOI: 10.3390/life1002001610.3390/life10020016717516332054054
- 4. McDonnell A, Rex JH, Goossens H, Bonten M, Fowler VGJ, Dane A. Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. Clin Infect Dis an Off Publ Infect Dis Soc Am. 2016 Aug;63 Suppl 2(Suppl 2):S57–9. DOI: 10.1093/cid/ciw24410.1093/cid/ciw244496759227481955
- 5. Adeolu M, Alnajar S, Naushad S, S Gupta R. Genome-based phylogeny and taxonomy of the “Enterobacteriales”: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int J Syst Evol Microbiol. 2016 Dec;66(12):5575–99. DOI: 10.1099/ijsem.0.00148510.1099/ijsem.0.00148527620848
- 6. Gajdács M, Urbán E. Comparative Epidemiology and Resistance Trends of Proteae in Urinary Tract Infections of Inpatients and Outpatients: A 10-Year Retrospective Study. Antibiot (Basel, Switzerland). 2019 Jul;8(3). DOI: 10.3390/antibiotics803009110.3390/antibiotics8030091678386231373311
- 7. Girlich D, Bonnin RA, Dortet L, Naas T. Genetics of Acquired Antibiotic Resistance Genes in Proteus spp. Front Microbiol. 2020;11:256. DOI: 10.3389/fmicb.2020.0025610.3389/fmicb.2020.00256704675632153540
- 8. Abdallah M, Balshi A. First literature review of carbapenem-resistant Providencia. New microbes new Infect. 2018 Sep;25:16–23. DOI: 10.1016/j.nmni.2018.05.00910.1016/j.nmni.2018.05.009603124129983987
- 9. O’Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000 Oct;13(4):534–46. DOI: 10.1128/CMR.13.4.53410.1128/CMR.13.4.5348894711023955
- 10. Tumbarello M, Citton R, Spanu T, Sanguinetti M, Romano L, Fadda G, et al. ESBL-producing multidrug-resistant Providencia stuartii infections in a university hospital. J Antimicrob Chemother. 2004 Feb;53(2):277–82. DOI: 10.1093/jac/dkh04710.1093/jac/dkh04714688041
- 11. Tumbarello M, Trecarichi EM, Fiori B, Losito AR, D’Inzeo T, Campana L, et al. Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 2012 Jun;56(6):3224–31. DOI: 10.1128/AAC.05966-1110.1128/AAC.05966-11337081522450979
- 12. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Intrinsic resistance and Unusual phenotypes V. 3.2 [Internet]. EUCAST Expert Rules. 2020. Available from: http://www.eucast.org/expert_rules_and_intrinsic_resistance/
- 13. Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection. 2020 Sep;1–17. DOI: 10.20944/preprints202006.0173. v110.20944/preprints202006.0173.v1
- 14. Lob S, Kazmierczak K, Stone G, Sahm DF. 680. In vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa from ICU and Non-ICU Wards Collected in Latin America and Globally as Part of the ATLAS Surveillance Program 2016–2017. Vol. 6, Open Forum Infectious Diseases. 2019. p. S310. DOI: 10.1093/ofid/ofz360.74810.1093/ofid/ofz360.748
- 15. Armengol E, Asunción T, Vi-as M, Sierra JM. When Combined with Colistin, an Otherwise Ineffective Rifampicin-Linezolid Combination Becomes Active in Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Microorganisms. 2020 Jan;8(1). DOI: 10.3390/microorganisms801008610.3390/microorganisms8010086702333931936387
- 16. Zhou Y-F, Liu P, Zhang C-J, Liao X-P, Sun J, Liu Y-H. Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat Escherichia coli Harboring bla (NDM-) (5) and mcr-1. Front Microbiol. 2019;10:2957. DOI: 10.3389/fmicb.2019.0295710.3389/fmicb.2019.02957696040431969868
- 17. Jacoby GA. AmpC β-Lactamases. Clin Microbiol Rev [Internet]. 2009 Jan 1;22(1):161 LP - 182. Available from: http://cmr.asm.org/content/22/1/161.abstract DOI: 10.1128/CMR.00036-0810.1128/CMR.00036-08262063719136439
- 18. Oikonomou O, Liakopoulos A, Phee LM, Betts J, Mevius D, Wareham DW. Providencia stuartii Isolates from Greece: Co-Carriage of Cephalosporin (blaSHV-5, blaVEB-1), Carbapenem (blaVIM-1), and Aminoglycoside (rmtB) Resistance Determinants by a Multi-drug-Resistant Outbreak Clone. Microb Drug Resist. 2016 Jul;22(5):379–86. DOI: 10.1089/mdr.2015.021510.1089/mdr.2015.021527380549
- 19. Lee H-W, Kang H-Y, Shin K-S, Kim J. Multidrug-resistant Providencia isolates carrying blaPER-1, blaVIM-2, and armA. J Microbiol. 2007 Jul 1;45:272–4.
- 20. Mahrouki S, Chihi H, Amel B, Moussa M, Belhadj O. First characterization of a Providencia stuartii clinical isolate from a Tunisian intensive care unit coproducing VEB-1-a, OXA-2, qnrA6 and aac(6 ‘)-Ib-cr determinants. Braz J Infect Dis. 2013 Dec 27;18. DOI: 10.1016/j.bjid.2013.10.00410.1016/j.bjid.2013.10.00424378226
- 21. Liakopoulos A, Oikonomou O, Wareham DW. Draft Genome Sequence of Providencia stuartii PS71, a Multidrug-Resistant Strain Associated with Nosocomial Infections in Greece. Genome Announc. 2017 Mar;5(12). DOI: 10.1128/genomeA.00056-1710.1128/genomeA.00056-17536422228336597
- 22. Molnár S, Vas K, Székely E. Carbapenemase Producing Enterobacterales in Romania: Investigating the Origins. Rev Rom Med Lab. 2020 Jul 1;28:341–8. DOI: 10.2478/rrlm-2020-002710.2478/rrlm-2020-0027
- 23. Poirel L, Schrenzel J, Cherkaoui A, Bernabeu S, Renzi G, Nordmann P. Molecular analysis of NDM-1-producing enterobacterial isolates from Geneva, Switzerland. J Antimicrob Chemother. 2011 Aug;66(8):1730–3. DOI: 10.1093/jac/dkr17410.1093/jac/dkr17421628303
- 24. Főldes A, Bilca D-V, Székely E. Phenotypic and molecular identification of carbapenemase-producing Enterobacteriaceae - challenges in diagnosis and treatment. Rev Rom Med Lab. 2018 Apr 1;26:221–30. DOI: 10.2478/rrlm-2018-001810.2478/rrlm-2018-0018
- 25. Guclu A, Guney M, Sig AK, Kilic S, Baysallar M. Arising Prevalence of OXA-48 producer Escherichia coli and OXA-48 with NDM co-producer Klebsiella pneumoniae Strains. Rev Rom Med Lab. 2019 Jul 14;27:319–26. DOI: 10.2478/rrlm-2019-003010.2478/rrlm-2019-0030
Language: English
Page range: 53 - 64
Submitted on: Oct 19, 2020
Accepted on: Dec 11, 2020
Published on: Jan 29, 2021
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2021 Corina Musuroi, Monica Licker, Maria Rus, Edward Seclaman, Delia Muntean, Silvana Vulpie, Luminita Baditoiu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.